Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.80 - $486.53
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$6.37M
Enterprise Value-$6.04M
Total Cash (Recent Filing)$21.62M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1684.47
Shares Outstanding1,181,725
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit74.57
Enterprise Value/Ebitda0.23
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data (Pipeline)Robust interim AML results (high clinical benefit and remission rates, MRD negativity, no CRS) materially de-risk mipletamig's clinical profile. Durable improvement in safety/efficacy versus standards supports long-term positioning as a combinable frontline option and strengthens licensing and regulatory prospects.
Proprietary PlatformAptevo's proprietary ADAPTIR platforms provide a durable technological foundation for multi-specific biologics. A platform model supports multiple assets, enables partner licensing and collaboration revenue streams, and creates potential competitive advantages across oncology and hematology beyond any single candidate.
Improved Capital StructureMaterial reduction in leverage versus prior stressed levels indicates a healthier balance-sheet footing. Lower absolute debt provides more financial flexibility and reduces creditor pressure, improving runway and strategic optionality even as cash burn continues, supporting longer-term development execution.
Bears Say
Zero RevenueThe company lacks product-derived recurring revenue, reporting $0 in 2023–2025 and persistent operating losses. Over the medium term this means reliance on milestone/collaboration receipts and financing for operations, limiting self-sufficiency and increasing execution risk if partnerships or milestones delay.
High Cash BurnSustained large negative operating and free cash flows erode runway and force repeated external funding. Worsening cash burn in 2024–2025 constrains investment flexibility, raises default/dilution risk, and means long-term development depends on raising capital rather than internal cash generation.
Financing / Dilution RiskApproved standby equity capacity secures funding access but creates a structural reliance on equity markets and potential material dilution. Ongoing dependence on such facilities can limit strategic choices, pressure existing holders, and raise governance considerations as development capital needs persist.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.80 and its highest was $486.53 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $6.37M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 18 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported $1684.47 earnings per share for the quarter, beating the consensus estimate of -$5.94 by $1690.41.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,181,725 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of $1684.47 in its last earnings report, beating expectations of -$5.94. Following the earnings report the stock price went up 1.921%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
1.08% Mutual Funds
<0.01% Other Institutional Investors
96.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---